Vidac Pharma will participate to the HTID5 as a fully sponsored guest speaker
London (UK) and Rehovot (Israel) June 16th, 2023 - Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com
As one of three laureate of the Prize for Innovation it received during the Paris HealthTech Innovation Days HTID-4 in October 2022, Vidac Pharma will participate as a fully sponsored guest to the HTID-5 a conference with more than 800 participants of the Healthtech industry to take place on October 24 and 25 in Paris. The HTID initiative sees itself as the most important European gathering of innovative companies, investors and key speakers and is a highly competitive place for Pharma and Biotech companies to be included in the program.
“We feel honored to have been chosen again for one of the most effective gathering for companies like ours with a great organization of a combination of one to one meetings with investors and key presentations by the best specialists in the field” said Max Herzberg the Chairman and CEO of Vidac Pharma. “We expect to present some of the key advances our company made through the revolutionary mode of action of our anti cancer drug candidates”
Rehovot (Israel) and London (UK)
About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.
Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
+972-54-4257381
+972 (0)779300647
